Tarsier Pharma's filings and July 2026 upsizing to target roughly $50 million in proceeds at an $8–$10 price range implied a post-money valuation near $300 million, yet the offering has not priced or listed on NYSE American as of mid-August. This absence of execution, despite an FDA Special Protocol Assessment for the Tarsier-04 Phase 3 trial in non-infectious uveitis, reflects subdued biotech IPO demand, limited institutional appetite for clinical-stage assets without revenue, and prevailing equity-market conditions that have kept small-cap windows largely closed. The 98.6% market-implied probability of no IPO before September 2026 embeds these headwinds while still leaving room for catalysts such as a material clinical data release, sector-wide sentiment shift, or revised terms that could reopen the path to listing.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วNo IPO before September 2026 98.6%
$400M-$450M 2.6%
$250M-$300M 1.8%
$350M-$400M 1.6%
$15,117 ปริมาณ
$15,117 ปริมาณ
Jul 9, 2026
<$250M
<1%
$250M-$300M
2%
$300M-$350M
<1%
$350M-$400M
2%
$400M-$450M
3%
>$450M
<1%
No IPO before September 2026
99%
No IPO before September 2026 98.6%
$400M-$450M 2.6%
$250M-$300M 1.8%
$350M-$400M 1.6%
$15,117 ปริมาณ
$15,117 ปริมาณ
Jul 9, 2026
<$250M
$907 ปริมาณ
<1%
$250M-$300M
$979 ปริมาณ
2%
$300M-$350M
$561 ปริมาณ
<1%
$350M-$400M
$561 ปริมาณ
2%
$400M-$450M
$349 ปริมาณ
3%
>$450M
$680 ปริมาณ
<1%
No IPO before September 2026
$11,080 ปริมาณ
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's filings and July 2026 upsizing to target roughly $50 million in proceeds at an $8–$10 price range implied a post-money valuation near $300 million, yet the offering has not priced or listed on NYSE American as of mid-August. This absence of execution, despite an FDA Special Protocol Assessment for the Tarsier-04 Phase 3 trial in non-infectious uveitis, reflects subdued biotech IPO demand, limited institutional appetite for clinical-stage assets without revenue, and prevailing equity-market conditions that have kept small-cap windows largely closed. The 98.6% market-implied probability of no IPO before September 2026 embeds these headwinds while still leaving room for catalysts such as a material clinical data release, sector-wide sentiment shift, or revised terms that could reopen the path to listing.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Jul 7, 2026, 9:12 AM ET
ปริมาณการซื้อขาย
$15,117วันสิ้นสุด
Jul 9, 2026ตลาดเปิดเมื่อ
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's filings and July 2026 upsizing to target roughly $50 million in proceeds at an $8–$10 price range implied a post-money valuation near $300 million, yet the offering has not priced or listed on NYSE American as of mid-August. This absence of execution, despite an FDA Special Protocol Assessment for the Tarsier-04 Phase 3 trial in non-infectious uveitis, reflects subdued biotech IPO demand, limited institutional appetite for clinical-stage assets without revenue, and prevailing equity-market conditions that have kept small-cap windows largely closed. The 98.6% market-implied probability of no IPO before September 2026 embeds these headwinds while still leaving room for catalysts such as a material clinical data release, sector-wide sentiment shift, or revised terms that could reopen the path to listing.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$15,117วันสิ้นสุด
Jul 9, 2026ตลาดเปิดเมื่อ
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's filings and July 2026 upsizing to target roughly $50 million in proceeds at an $8–$10 price range implied a post-money valuation near $300 million, yet the offering has not priced or listed on NYSE American as of mid-August. This absence of execution, despite an FDA Special Protocol Assessment for the Tarsier-04 Phase 3 trial in non-infectious uveitis, reflects subdued biotech IPO demand, limited institutional appetite for clinical-stage assets without revenue, and prevailing equity-market conditions that have kept small-cap windows largely closed. The 98.6% market-implied probability of no IPO before September 2026 embeds these headwinds while still leaving room for catalysts such as a material clinical data release, sector-wide sentiment shift, or revised terms that could reopen the path to listing.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย